Empowered Funds LLC Purchases New Shares in Thermo Fisher Scientific Inc. $TMO

Empowered Funds LLC bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 36,395 shares of the medical research company's stock, valued at approximately $18,247,000.

Other large investors also recently added to or reduced their stakes in the company. High Note Wealth LLC boosted its stake in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after buying an additional 29 shares during the period. Swiss RE Ltd. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $28,000. Kilter Group LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $25,000. Legacy Wealth Managment LLC ID grew its holdings in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after purchasing an additional 22 shares during the last quarter. Finally, Birchwood Financial Partners Inc. purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth about $29,000. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of the company's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares of the company's stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 1.4%

Shares of NYSE:TMO opened at $621.87 on Friday. The business's 50 day moving average is $558.64 and its 200 day moving average is $512.08. The stock has a market cap of $229.94 billion, a P/E ratio of 33.45, a price-to-earnings-growth ratio of 2.57 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. During the same period in the prior year, the business earned $4.28 EPS. The business's revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. HSBC cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating and dropped their price objective for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a research note on Wednesday, August 5th. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research report on Monday, July 6th. Finally, KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source